High dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase.

Laila HellkvistEric HjalmarssonDan WeinfeldÅslög DahlAgneta KarlssonMarit WestmanKarin LundkvistOla WinqvistSusanna Kumlien GeorénUlla WestinLars-Olaf Cardell

Published in: Allergy (2021)

Intralymphatic immunotherapy in high doses after SCIT appears to further reduce grass pollen-induced seasonal symptoms and may be considered as an add-on treatment for patients that do not reach full symptom control after SCIT. Up-dosing schedules de novo with three monthly injections that exceeds 3000 SQ-U should be avoided.

Keyphrases

high dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported
physical activity
high glucose
ultrasound guided
depressive symptoms
drug induced
stress induced